Clinical Trials Logo

CHD Risk-Equivalent Disease clinical trials

View clinical trials related to CHD Risk-Equivalent Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00685776 Completed - Clinical trials for Coronary Heart Disease (CHD)

Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)

DEFINE
Start date: March 24, 2008
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy of anacetrapib (100 mg) for 24 weeks relative to placebo, on plasma concentrations of Low Density Lipoprotein Cholesterol and assess the safety and tolerability of anacetrapib (100 mg) in participants with CHD/CHD risk-equivalent disease on stable dose regimen of statin with or without other lipid-modifying therapy. The two year extension to this study will further evaluate the long-term safety profile and efficacy of anacetrapib in CHD/CHD-risk equivalent patients who are on ongoing therapy with a statin with or without other lipid-modifying therapy.